Fibromyalgia:
Indications for: LYRICA
Fibromyalgia.
Adult Dosage:
Initially 75mg twice daily, may increase to 150mg twice daily within 1 week as tolerated; max 450mg/day. Renal impairment (CrCl <60mL/min): reduce dose (see full labeling); hemodialysis: give supplemental dose after session.
Children Dosage:
Not established.
LYRICA Warnings/Precautions:
Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. Monitor for new or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood/behavior. Underlying respiratory depression; monitor and consider initiating at a low dose. CHF (w. NYHA Class III/IV status). Ocular conditions. Diabetes (monitor skin integrity). Avoid abrupt cessation (taper over ≥1 week). Pregnancy. Nursing mothers: not recommended.
See Also:
LYRICA Classification:
Alpha-2 delta ligand.
LYRICA Interactions:
Increased risk for serious respiratory depression when concomitant CNS depressants, opioids. Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
Adverse Reactions:
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention); elevated creatine kinase, decreased platelets, PR prolongation, male-mediated teratogenicity; may be tumorigenic. Also in children: increased appetite.
Note:
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
How Supplied:
Caps—90; Soln—16oz
Nonnarcotic analgesics:
Indications for: LYRICA
Neuropathic pain associated with diabetic peripheral neuropathy (DPN) or spinal cord injury. Postherpetic neuralgia (PHN).
Adult Dosage:
DPN: initially 50mg 3 times daily, may increase to 100mg 3 times daily within 1 week. Spinal cord injury: initially 75mg twice daily, may increase to 150mg twice daily within 1 week, then max 600mg/day after 2 weeks as tolerated. PHN: initially 75mg twice daily or 50mg 3 times daily; max 300mg/day after 1 week then 600mg/day after 2 weeks as tolerated (see full labeling). For all: renal impairment (CrCl <60mL/min): reduce dose (see full labeling); hemodialysis: give supplemental dose after session.
Children Dosage:
Not established.
LYRICA Warnings/Precautions:
Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. Monitor for new or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood/behavior. Underlying respiratory depression; monitor and consider initiating at a low dose. CHF (w. NYHA Class III/IV status). Ocular conditions. Diabetes (monitor skin integrity). Avoid abrupt cessation (taper over ≥1 week). Pregnancy. Nursing mothers: not recommended.
See Also:
LYRICA Classification:
Alpha-2 delta ligand.
LYRICA Interactions:
Increased risk for serious respiratory depression when concomitant CNS depressants, opioids. Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
Adverse Reactions:
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention); elevated creatine kinase, decreased platelets, PR prolongation, male-mediated teratogenicity; may be tumorigenic. Also in children: increased appetite.
Note:
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
How Supplied:
Caps—90; CR tabs—30; Soln—16oz
Seizure disorders:
Indications for: LYRICA
Adjunct in partial onset seizures.
Adult Dosage:
Give in 2–3 divided doses. ≥17yrs: initially 150mg/day; max 600mg/day. Renal impairment (CrCl <60mL/min): reduce dose (see full labeling); hemodialysis: give supplemental dose after session.
Children Dosage:
<1 month: not established. Give in 2–3 divided doses (3 divided doses for <4yrs). ≥1 month (<30kg): initially 3.5mg/kg/day; max 14mg/kg/day; (≥30kg): initially 2.5mg/kg/day, max 10mg/kg/day (up to 600mg/day). Renal impairment (CrCl <60mL/min): not established.
LYRICA Warnings/Precautions:
Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. Monitor for new or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood/behavior. Underlying respiratory depression; monitor and consider initiating at a low dose. CHF (w. NYHA Class III/IV status). Ocular conditions. Diabetes (monitor skin integrity). Avoid abrupt cessation (taper over ≥1 week). Pregnancy. Nursing mothers: not recommended.
See Also:
LYRICA Classification:
Alpha-2 delta ligand.
LYRICA Interactions:
Increased risk for serious respiratory depression when concomitant CNS depressants, opioids. Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
Adverse Reactions:
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention); elevated creatine kinase, decreased platelets, PR prolongation, male-mediated teratogenicity; may be tumorigenic. Also in children: increased appetite.
Note:
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
How Supplied:
Caps—90; Soln—16oz
